Skip to content

Study · Animal study (in vivo) · mouse · 2020

8 results

Effects of ghrelin receptor activation on forebrain dopamine release, conditioned fear and fear extinction in C57BL/6J mice.

Pierre A, Van Schuerbeek A, Allaoui W, Van Laere S, Singewald N, Van Eeckhaut A, Smolders I, De Bundel D

Journal of neurochemistry25 Mar 2020Cited by 10 (Europe PMC)

PMID32128814 (opens in a new tab)DOI10.1111/jnc.14996 (opens in a new tab)PepBankPUB-32128814
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male C57BL/6J mice, systemic MK0677 at the tested dose induced food intake.

    In plain wordsIn mice, systemic MK0677 induced food intake.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseFood intake after systemic administration
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Our data show that systemic administration of the ghrelin receptor agonist MK0677, in a dose that induces food intake, has no significant effect on auditory fear processing and does not significantly affect dopamine release in the nucleus accumbens of male C57BL/6J mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male C57BL/6J mice, systemic MK0677 had no significant effect on auditory fear processing.

    In plain wordsIn mice, systemic MK0677 did not significantly affect auditory fear processing.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeAuditory fear processing after systemic administration
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Our data show that systemic administration of the ghrelin receptor agonist MK0677, in a dose that induces food intake, has no significant effect on auditory fear processing and does not significantly affect dopamine release in the nucleus accumbens of male C57BL/6J mice.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In male C57BL/6J mice, systemic MK0677 did not significantly affect nucleus accumbens dopamine release.

    In plain wordsIn mice, systemic MK0677 did not significantly affect dopamine release in the nucleus accumbens.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeAccumbens dopamine after systemic administration
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Our data show that systemic administration of the ghrelin receptor agonist MK0677, in a dose that induces food intake, has no significant effect on auditory fear processing and does not significantly affect dopamine release in the nucleus accumbens of male C57BL/6J mice.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, local MK0677 administration into the ventral tegmental area significantly increased food intake.

    In plain wordsIn mice, MK0677 given into the ventral tegmental area significantly increased food intake.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseFood intake after VTA administration
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · local administration into ventral tegmental areaAs given in this study (mouse).

    Source sentences

    Summary
    Local administration of the ghrelin receptor agonist MK0677 into the ventral tegmental area significantly increases food intake and it also significantly increased dopamine release in the nucleus accumbens, the medial prefrontal cortex and the amygdala.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice, MK0677 in the ventral tegmental area significantly increased nucleus accumbens dopamine release.

    In plain wordsIn mice, MK0677 in the ventral tegmental area increased dopamine release in the nucleus accumbens.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseAccumbens dopamine after VTA administration
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · local administration into ventral tegmental areaAs given in this study (mouse).

    Source sentences

    Summary
    Local administration of the ghrelin receptor agonist MK0677 into the ventral tegmental area significantly increases food intake and it also significantly increased dopamine release in the nucleus accumbens, the medial prefrontal cortex and the amygdala.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice, MK0677 in the ventral tegmental area significantly increased medial prefrontal cortex dopamine release.

    In plain wordsIn mice, MK0677 in the ventral tegmental area increased dopamine release in the medial prefrontal cortex.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreasePrefrontal dopamine after VTA administration
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · local administration into ventral tegmental areaAs given in this study (mouse).

    Source sentences

    Summary
    Local administration of the ghrelin receptor agonist MK0677 into the ventral tegmental area significantly increases food intake and it also significantly increased dopamine release in the nucleus accumbens, the medial prefrontal cortex and the amygdala.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice, MK0677 in the ventral tegmental area significantly increased amygdala dopamine release.

    In plain wordsIn mice, MK0677 in the ventral tegmental area increased dopamine release in the amygdala.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseAmygdala dopamine after VTA administration
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · local administration into ventral tegmental areaAs given in this study (mouse).

    Source sentences

    Summary
    Local administration of the ghrelin receptor agonist MK0677 into the ventral tegmental area significantly increases food intake and it also significantly increased dopamine release in the nucleus accumbens, the medial prefrontal cortex and the amygdala.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice, MK0677 in the ventral tegmental area did not significantly affect auditory fear extinction.

    In plain wordsIn mice, MK0677 in the ventral tegmental area did not significantly affect auditory fear extinction.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeAuditory fear extinction after VTA administration
    Study

    mousen: not reported in source

    male C57BL/6J mice
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    Dose not stated · local administration into ventral tegmental areaAs given in this study (mouse).

    Source sentences

    Summary
    Nevertheless, it did not significantly affect auditory fear extinction.
    1 context sentence
    Summary · context
    Local administration of the ghrelin receptor agonist MK0677 into the ventral tegmental area significantly increases food intake and it also significantly increased dopamine release in the nucleus accumbens, the medial prefrontal cortex and the amygdala.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.